Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Pharmaceuticals (Nasdaq:SNDX) will host an R&D Day on July 14, 2026, at 8:30 AM ET in New York City.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq:SNDX) will host an R&D Day on July 14, 2026, at 8:30 AM ET in New York City. Management and key opinion leaders will present updates on late-stage revumenib and axatilimab programs and discuss ongoing trials.

The event will also cover new early-stage assets and plans to leverage company capabilities to bring additional cancer treatment options to patients. A live webcast and limited-time replay will be available in the Investor section of www.syndax.com.

Argus Jun 1 session

-3.78% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – SNDX

On Jun 1, the day this news came out, SNDX closed 3.78% below the previous close.

Data tracked by StockTitan Argus for the Jun 1 session.

Key Figures

R&D Day date: July 14, 2026 Event time: 8:30 AM ET

R&D Day date

July 14, 2026

Scheduled company R&D Day event

Event time

8:30 AM ET

Start time of R&D Day in New York City

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   ASCO abstracts accepted

   24h Move

   +0.9%

   Multiple Revuforj abstracts accepted for ASCO 2026, including oral presentation.

2. May 20

   Investor conferences

   24h Move

   +3.6%

   Participation in several major healthcare investor conferences with management presentations.

3. May 12

   EHA abstracts accepted

   24h Move

   -4.5%

   Twelve Revuforj abstracts accepted for EHA 2026 across leukemia settings.

4. May 06

   Inducement grants

   24h Move

   -0.5%

   Stock option inducement awards granted to new employees under 2023 Inducement Plan.

5. Apr 30

   Q1 2026 earnings

   24h Move

   -10.8%

   Reported strong Q1 revenue growth and reiterated high 2026 R&D and SG&A outlook.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

idiopathic pulmonary fibrosis, chronic graft-versus-host disease, acute leukemia

3 terms

idiopathic pulmonary fibrosis medical

"ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host..."

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

chronic graft-versus-host disease medical

"ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host..."

A long-lasting complication that can occur after someone receives donated bone marrow or stem cells, where the donor’s immune cells attack the recipient’s healthy tissues and organs. It matters to investors because it drives demand for specialized drugs, long-term medical care and new therapies, affects clinical trial design and regulatory decisions, and can materially influence costs, revenues and risk profiles for companies in transplant and immunology markets.

acute leukemia medical

"newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia."

A fast-moving cancer of the blood and bone marrow in which immature blood cells multiply uncontrollably and crowd out healthy cells, leading to severe infection risk, bleeding and anemia. For investors, acute leukemia represents an urgent medical need that can drive rapid clinical development, regulatory priority and sizable treatment markets — like a broken dam that demands immediate repair, creating both high potential returns and high risk for companies and drugs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City. The R&D Day will feature presentations by Syndax’s management team and key opinion leaders.

The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients.

A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Syndax (SNDX) hosting its R&D Day in 2026?

Syndax is hosting its R&D Day on July 14, 2026, at 8:30 AM ET. According to the company, the event will take place in New York City and feature presentations on late-stage programs and early-stage assets.

What programs will Syndax (SNDX) highlight at its July 14, 2026 R&D Day?

Syndax will highlight its late-stage revumenib and axatilimab programs at the July 14, 2026 R&D Day. According to Syndax, updates will include ongoing trials and discussion of new early-stage assets and broader development plans.

Which diseases are covered in Syndax (SNDX) ongoing trials to be discussed at the 2026 R&D Day?

The R&D Day will cover ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. According to Syndax, these trials are part of its late-stage revumenib and axatilimab programs.

Will Syndax (SNDX) provide a webcast for its July 14, 2026 R&D Day?

Yes, Syndax will provide a live webcast of the July 14, 2026 R&D Day. According to the company, investors can access the webcast and a limited-time replay via the Investor section of its website at www.syndax.com.

What early-stage assets will Syndax (SNDX) discuss during the 2026 R&D Day event?

Syndax plans to discuss its new early-stage assets during the 2026 R&D Day. According to Syndax, the company will outline how it intends to leverage its capabilities and resources to bring additional treatment options to more cancer patients.

Who will present at the Syndax (SNDX) R&D Day on July 14, 2026?

Presentations will be delivered by Syndax’s management team and key opinion leaders at the R&D Day. According to Syndax, these speakers will provide updates on late-stage programs, ongoing trials, and the company’s emerging early-stage pipeline.